• 1
    Dalquen P,Kleiber B,Grilli B,Herzog M,Bubendorf L,Oberholze M. DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer (Cancer Cytopathol). 2002; 96: 374379.
  • 2
    Dyrskjot L. Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarray in cancer diagnostics. Expert Rev Mol Diagn. 2003; 3: 635647.
  • 3
    Jung I,Reeder JE,Cox C, et al. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J Urol. 1999; 162: 19001903.
  • 4
    Phillips JL,Richardson IC. Aneuploidy in bladder cancer: the utility of fluorescence in situ hybridization in clinical practice. BJU Int. 2006; 98: 3337.
  • 5
    Bubendorf L,Grilli G,Sauter G,Mihatsch MJ,Gasser TC,Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001; 116: 7986.
  • 6
    Raitanen MP,Kaasinen E,Lukkarinen O, et al. Analysis of false-positive BTA Stat test results in patients followed up for bladder cancer. Urology. 2001; 57: 680684.
  • 7
    Jones SJ. DN. A-based molecular cytology for bladder cancer surveillance. Urology 2006; 67( Suppl 3A): 3547.
  • 8
    Mian C,Pycha A,Wiener H,Haitel A,Lodde M,Marberger M. Immunocyte: a new tool for detecting transitional cell cancer of the urinary tract. J Urol. 1999; 161: 14861489.
  • 9
    Ishiwata S,Takahashi S,Homma Y, et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology. 2001; 57: 811815.
  • 10
    Halling KC,King W,Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000; 164: 17681775.
  • 11
    Halachmi S,Madeb R,Kravtsov A,Moskovitz B,Halachmi N,Nativ O. Bladder cancer — genetic overview. Med Sci Monit. 2001; 7: 164168.
  • 12
    Sandberg AA. Cytogenetics and molecular genetics of bladder cancer: a personal view. Am J Med Genet. 2002; 115: 173182.
  • 13
    Tsukamoto M,Matsuyama H,Oba K,Yoshihiro S,Takahashi M,Naito K. Numerical aberrations of chromosome 9 in bladder cancer: a possible prognostic marker for early tumor recurrence. Cancer Genet Cytogenet. 2002; 134: 4145.
  • 14
    Marano A,Pan Y,Li C, et al. Chromosomal numerical aberrations detected by fluorescence in situ hybridization on bladder washings from patients with bladder cancer. Eur Urol. 2000; 37: 358365.
  • 15
    Kipp BR,Karnes RJ,Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005; 173: 401404.
  • 16
    Sokolova IA,Halling KC,Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000; 2: 116123.
  • 17
    Veeramachaneni R,Nordberg ML,Shi R,Herrera GA,Turbat-Herrera EA. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol. 2003; 28: 301307.
  • 18
    Daniely M,Rona R,Kaplan T, et al. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology. 2005; 66: 13541359.
  • 19
    Epstein JI,Amin MB,Reuter VR,Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22: 14351448.
  • 20
    Bielorai B,Golan H,Trakhtenbrot L, et al. Combined analysis of morphology and fish in follow-up of minimal residual disease (MRD) in a child with Ph+ acute lymphoblastic leukemia (ALL). Cancer Genet Cytogenet. 2002; 138: 6468.
  • 21
    Kaplinsky C,Trakhtenbrot L,Hardan I, et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSFM. Bone Marrow Transplant. 2003; 32: 3134.
  • 22
    Shimoni A,Nagler A,Kaplinsky C, et al. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using BioView (DuetTM) combined morphological and cytological analysis. Leukemia. 2002; 16: 14131418.
  • 23
    Skacel M,Fahmy M,Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003; 169: 21012105.
  • 24
    Junker K,Fritsch T,Hartmann A,Schulze W,Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res. 2006; 114: 279283.